Lexeo Therapeutics
Develops genetic medicines for inherited cardiovascular disease and select CNS disorders.
$4.77
After-hours close−0.10 (−1.95%)
At close$4.87(−2.51%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 101.74%Insiders 1.14%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 78.52M · Float 47.42M · 60.4% free float
Institutions13F, as of Mar 31, 2026
143 holders · 79.89M shares · 21 new positions · 77 increased · 41 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 6.18M | 7.88% | +1.42M | May 15, 2026 |
| BlackRock, Inc. | 5.11M | 6.51% | +203.3K | May 13, 2026 |
| Affinity Asset Advisors, LLC | 5.05M | 6.43% | +1.85M | May 14, 2026 |
| Ra Capital Management, L.P. | 5.00M | 6.37% | 0 | May 15, 2026 |
| Janus Henderson Group PLC | 4.98M | 6.34% | −533.2K | May 18, 2026 |
| Vestal Point Capital, LP | 4.48M | 5.70% | 0 | May 15, 2026 |
| Frazier Life Sciences Management, L.P. | 4.42M | 5.64% | 0 | May 15, 2026 |
| Citadel Advisors LLC | 3.83M | 4.88% | +60.7K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.99% | 7.29M | 13G | Dec 8, 2025 ↗ |
| Balyasny Asset Management L.P. | 9.69% | 7.18M | 13G | May 15, 2026 ↗ |
| Paradigm BioCapital Advisors LP | 8.30% | 6.18M | 13G | May 15, 2026 ↗ |
| Affinity Healthcare Fund, LP | 7.75% | 4.25M | 13G | Jun 4, 2025 ↗ |
| Suvretta Capital Management, LLC | 7.70% | 5.67M | 13G | Apr 13, 2026 ↗ |
| Vestal Point Capital, LP | 7.50% | 4.12M | 13G | Nov 14, 2025 ↗ |
| Citadel Advisors LLC | 7.20% | 5.41M | 13G | Feb 17, 2026 ↗ |
| Affinity Asset Advisors, LLC | 7.10% | 5.22M | 13G | Jan 29, 2026 ↗ |
| RA Capital Management, L.P. | 6.90% | 5.00M | 13G | Oct 27, 2025 ↗ |
| BlackRock, Inc. | 6.70% | 4.89M | 13G | Jan 21, 2026 ↗ |
| Mizuho Financial Group, Inc. | 6.60% | 2.20M | 13G | May 13, 2025 ↗ |
| State Street Corporation | 5.50% | 4.35M | 13G | Aug 7, 2026 ↗ |
| Frazier Life Sciences Public Fund, L.P. | 5.10% | 3.70M | 13G | Feb 13, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Richard Nolan Townsend | director, officer: Chief Executive Officer | 374.5K | 0.48% | Aug 19, 2026 |
| Jose Manuel Otero | officer: Chief Operating Officer | 136.2K | 0.17% | Aug 19, 2026 |
| Louis Edward Tamayo | officer: Chief Financial Officer | 92.9K | 0.12% | Aug 19, 2026 |
| Narinder Pal Bhalla | officer: Chief Medical Officer | 82.2K | 0.10% | Jul 1, 2026 |
| Eric Adler | officer: Chief Medical Officer | 72.6K | 0.09% | Nov 20, 2025 |
| Jenny Robertson | officer: Chief Legal Officer | 68.4K | 0.09% | Nov 20, 2025 |
| Tai Sandi See | officer: Chief Development Officer | 65.5K | 0.08% | Nov 20, 2025 |
3 ten-percent owners hold 4.53M shares by Form 4, outside the officers-and-directors figure above · 3 people have not refiled in the last 18 months (88.9K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Jose Manuel Oteroofficer: Chief Operating Officer | Sale | 1,304 | $4.96 | 136,178 |
| Aug 18, 2026 | Richard Nolan Townsenddirector, officer: Chief Executive Officer | Sale | 3,345 | $4.95 | 374,472 |
| Aug 18, 2026 | Louis Edward Tamayoofficer: Chief Financial Officer | Sale | 4,117 | $4.91 | 92,907 |
| Jul 1, 2026 | Richard Nolan Townsenddirector, officer: Chief Executive Officer | Sale | 25,947 | $4.48 | 377,817 |
| Jul 1, 2026 | Narinder Pal Bhallaofficer: Chief Medical Officer | Sale | 22,306 | $4.42 | 82,194 |
| Jul 1, 2026 | Jose Manuel Oteroofficer: Chief Operating Officer | Sale | 4,666 | $4.48 | 137,482 |
| Jul 1, 2026 | Louis Edward Tamayoofficer: Chief Financial Officer | Sale | 4,641 | $4.49 | 97,024 |
| May 18, 2026 | Richard Nolan Townsenddirector, officer: Chief Executive Officer | Sale | 3,342 | $5.06 | 336,764 |
| May 18, 2026 | Jose Manuel Oteroofficer: Chief Operating Officer | Sale | 1,302 | $5.07 | 130,088 |
| Apr 6, 2026 | Richard Nolan Townsenddirector, officer: Chief Executive Officer | Sale | 55,000 | $5.69 | 340,106 |
CongressHouse and Senate disclosures
Not reported.